Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NGM Stock Summary
In the News
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago.
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.59 per share a year ago.
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.59 per share a year ago.
NGM Bio to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming investor conferences.
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 13.46% and 166.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.28% and 12.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
After Plunging 59.4% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)
The heavy selling pressure might have exhausted for NGM Biopharmaceuticals (NGM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
3 Best Penny Stocks To Buy Before November According To Insiders
Penny stocks to buy according to insiders in October. The post 3 Best Penny Stocks To Buy Before November According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
NGM Financial details
NGM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.06 | 1.28 | 1.01 | 0.69 | 0.05 | |
Net income per share | -0.57 | -1.37 | -1.48 | -1.99 | -1.73 | |
Operating cash flow per share | -0.82 | -1.22 | -0.95 | -1.81 | -1.6 | |
Free cash flow per share | -0.89 | -1.25 | -0.97 | -1.83 | -1.62 | |
Cash per share | 6.85 | 4.31 | 4.75 | 3.4 | 1.78 | |
Book value per share | 6.58 | 4.09 | 4.35 | 3.25 | 1.8 | |
Tangible book value per share | 6.58 | 4.09 | 4.35 | 3.25 | 1.8 | |
Share holders equity per share | 6.58 | 4.09 | 4.35 | 3.25 | 1.8 | |
Interest debt per share | 0 | 0 | 0.14 | 0.11 | 0 | |
Market cap | 930M | 2.07B | 1.37B | 401.35M | 70.86M | |
Enterprise value | 684.4M | 1.93B | 1.22B | 333.28M | 12.05M | |
P/E ratio | -32.63 | -22.07 | -11.99 | -2.52 | -0.5 | |
Price to sales ratio | 8.98 | 23.75 | 17.53 | 7.25 | 16.04 | |
POCF ratio | -22.59 | -24.85 | -18.64 | -2.78 | -0.54 | |
PFCF ratio | -20.82 | -24.3 | -18.22 | -2.74 | -0.53 | |
P/B Ratio | 2.81 | 7.41 | 4.07 | 1.55 | 0.48 | |
PTB ratio | 2.81 | 7.41 | 4.07 | 1.55 | 0.48 | |
EV to sales | 6.61 | 22.07 | 15.71 | 6.02 | 2.73 | |
Enterprise value over EBITDA | -13.87 | -18.57 | -10.14 | -2 | -0.08 | |
EV to operating cash flow | -16.62 | -23.09 | -16.71 | -2.31 | -0.09 | |
EV to free cash flow | -15.32 | -22.58 | -16.34 | -2.28 | -0.09 | |
Earnings yield | -0.03 | -0.05 | -0.08 | -0.4 | -2.01 | |
Free cash flow yield | -0.05 | -0.04 | -0.05 | -0.36 | -1.88 | |
Debt to equity | 0 | 0 | 0.03 | 0.02 | 0 | |
Debt to assets | 0 | 0 | 0.03 | 0.02 | 0 | |
Net debt to EBITDA | 4.98 | 1.42 | 1.17 | 0.41 | 0.41 | |
Current ratio | 8.94 | 7.24 | 6.18 | 6.04 | 7.79 | |
Interest coverage | 0 | 0 | 0 | -44.76 | 0 | |
Income quality | 0.96 | 0.81 | 0.61 | 0.89 | 0.93 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.23 | 0.31 | 0.47 | 0.73 | 8.57 | |
Research and developement to revenue | 1.25 | 1.88 | 2.08 | 3.27 | 25.36 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.08 | 0.02 | 0.02 | 0.01 | 0.01 | |
Capex to revenue | -0.03 | -0.02 | -0.02 | -0.03 | -0.28 | |
Capex to depreciation | -0.46 | -0.29 | -0.28 | -0.46 | -0.56 | |
Stock based compensation to revenue | 0.13 | 0.18 | 0.34 | 0.59 | 6.5 | |
Graham number | 9.16 | 11.24 | 12.03 | 12.06 | 8.36 | |
ROIC | -0.1 | -0.34 | -0.32 | -0.6 | -0.99 | |
Return on tangible assets | -0.07 | -0.29 | -0.28 | -0.52 | -0.84 | |
Graham Net | 5.94 | 3.67 | 3.93 | 2.87 | 1.54 | |
Working capital | 315.53M | 265.84M | 317.93M | 241.02M | 136.36M | |
Tangible asset value | 330.72M | 280.04M | 335.65M | 259.56M | 148.64M | |
Net current asset value | 305.56M | 259.43M | 312.54M | 241.02M | 136.21M | |
Invested capital | 0 | 0 | 0.03 | 0.02 | 0 | |
Average receivables | 4.44M | 5.82M | 5.69M | 6.26M | 3.82M | |
Average payables | 7.4M | 9.34M | 7.45M | 6.85M | 5.72M | |
Average inventory | 0.5 | 1 | 1 | 1 | 0.5 | |
Days sales outstanding | 18.35 | 26.88 | 23.18 | 50 | 4.79 | |
Days payables outstanding | 25.49 | 21.51 | 242.41 | 515.6 | 490.06 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 19.89 | 13.58 | 15.75 | 7.3 | 76.16 | |
Payables turnover | 14.32 | 16.97 | 1.51 | 0.71 | 0.74 | |
Inventory turnover | 129.25M | 163.97M | 7.9M | 5.98M | 0 | |
ROE | -0.09 | -0.34 | -0.34 | -0.61 | -0.96 | |
Capex per share | -0.07 | -0.03 | -0.02 | -0.02 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.22 | 0.03 | 0.02 | 0.01 | 0 | |
Net income per share | -0.42 | -0.55 | -0.46 | -0.35 | -0.33 | |
Operating cash flow per share | -0.37 | -0.51 | -0.49 | -0.33 | -0.28 | |
Free cash flow per share | -0.38 | -0.52 | -0.49 | -0.33 | -0.28 | |
Cash per share | 3.32 | 2.82 | 2.35 | 2.01 | 1.78 | |
Book value per share | 3.17 | 2.69 | 2.33 | 2.05 | 1.8 | |
Tangible book value per share | 3.17 | 2.69 | 2.33 | 2.05 | 1.8 | |
Share holders equity per share | 3.17 | 2.69 | 2.33 | 2.05 | 1.8 | |
Interest debt per share | 0.09 | 0.02 | 0.03 | 0.02 | 0 | |
Market cap | 410.57M | 334.59M | 213.56M | 88.5M | 71.13M | |
Enterprise value | 342.5M | 271.12M | 163.04M | 38.4M | 12.31M | |
P/E ratio | -2.97 | -1.85 | -1.4 | -0.77 | -0.64 | |
Price to sales ratio | 22.58 | 148.91 | 150.08 | 152.06 | 431.08 | |
POCF ratio | -13.5 | -8 | -5.31 | -3.26 | -3.1 | |
PFCF ratio | -13.31 | -7.87 | -5.29 | -3.22 | -3.07 | |
P/B Ratio | 1.58 | 1.51 | 1.11 | 0.52 | 0.48 | |
PTB ratio | 1.58 | 1.51 | 1.11 | 0.52 | 0.48 | |
EV to sales | 18.84 | 120.66 | 114.58 | 65.98 | 74.62 | |
Enterprise value over EBITDA | -8.94 | -5.4 | -4.07 | -1.26 | -0.42 | |
EV to operating cash flow | -11.26 | -6.48 | -4.05 | -1.41 | -0.54 | |
EV to free cash flow | -11.1 | -6.38 | -4.04 | -1.4 | -0.53 | |
Earnings yield | -0.08 | -0.13 | -0.18 | -0.33 | -0.39 | |
Free cash flow yield | -0.08 | -0.13 | -0.19 | -0.31 | -0.33 | |
Debt to equity | 0.02 | 0.02 | 0.01 | 0.01 | 0 | |
Debt to assets | 0.02 | 0.02 | 0.01 | 0.01 | 0 | |
Net debt to EBITDA | 1.78 | 1.26 | 1.26 | 1.64 | 2.02 | |
Current ratio | 6.04 | 6.4 | 7.19 | 7.92 | 7.79 | |
Interest coverage | -18.87 | 19.71 | 0 | 0 | 0 | |
Income quality | 0.83 | 0.88 | 1.05 | 0.94 | 0.83 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.54 | 5.16 | 6.78 | 14.9 | 48.11 | |
Research and developement to revenue | 2.57 | 18.18 | 22.73 | 39.42 | 129.53 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.02 | 0 | 0.01 | 0.01 | |
Capex to revenue | -0.02 | -0.3 | -0.07 | -0.5 | -1.14 | |
Capex to depreciation | -0.72 | -1.1 | -0.19 | -0.54 | -0.36 | |
Stock based compensation to revenue | 0.48 | 3.8 | 5.25 | 11.01 | 38.16 | |
Graham number | 5.49 | 5.77 | 4.93 | 4.01 | 3.67 | |
ROIC | -0.13 | -0.21 | -0.19 | -0.17 | -0.2 | |
Return on tangible assets | -0.11 | -0.17 | -0.17 | -0.15 | -0.16 | |
Graham Net | 2.8 | 2.38 | 2.02 | 1.74 | 1.53 | |
Working capital | 241.02M | 204.63M | 175.98M | 154.69M | 136.36M | |
Tangible asset value | 259.56M | 220.93M | 192.12M | 169.81M | 148.64M | |
Net current asset value | 241.02M | 204.63M | 175.98M | 154.69M | 136.21M | |
Invested capital | 0.02 | 0.02 | 0.01 | 0.01 | 0 | |
Average receivables | 5.98M | 4.42M | 996.5K | 368K | 29K | |
Average payables | 6.01M | 10.87M | 9.57M | 5.27M | 3.84M | |
Average inventory | 1 | 749.5K | 1.5M | 749.5K | 0 | |
Days sales outstanding | 37.52 | 50.35 | 46.55 | 0 | 31.64 | |
Days payables outstanding | 682.92 | 1.07K | 470.91 | 844.2 | 518.11 | |
Days of inventory on hand | 0 | 120.56 | 120.56 | 0 | 0 | |
Receivables turnover | 2.4 | 1.79 | 1.93 | 0 | 2.84 | |
Payables turnover | 0.13 | 0.08 | 0.19 | 0.11 | 0.17 | |
Inventory turnover | 1.11M | 0.75 | 0.75 | 0 | 0 | |
ROE | -0.13 | -0.2 | -0.2 | -0.17 | -0.19 | |
Capex per share | -0.01 | -0.01 | 0 | 0 | 0 |
NGM Frequently Asked Questions
What is NGM Biopharmaceuticals, Inc. stock symbol ?
NGM Biopharmaceuticals, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol NGM
Is NGM Biopharmaceuticals, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $16.5. The lowest prediction is $4 and the highest is $29
What is NGM stock prediction ?
What is NGM Biopharmaceuticals, Inc. stock quote today ?
NGM Biopharmaceuticals, Inc. stock price is $1.575 today.
Is NGM Biopharmaceuticals, Inc. stock public?
Yes, NGM Biopharmaceuticals, Inc. is a publicly traded company.